Dementia Australia has welcomed the publication of the results of a trial showing that a new drug, donanemab, has been able to slow the progression of symptoms of early Alzheimer’s disease. Dementia Australia CEO Maree ...
Eli Lilly and Company’s new drug, donanemab, has shown promising results in slowing cognitive decline by 35% in people with early symptoms of Alzheimer’s disease. The drug, donanemab, has been shown to significantly slow cognitive ...